четверг, 20 октября 2016 г.

Teva Pharmaceutical Industries Ltd. (TEVA) Upgraded to Hold at Zacks Investment Research

Teva Pharmaceutical Industries Ltd. (TEVA) Upgraded to Hold at Zacks Investment Research


According to Zacks, "2016 is a transition year for Teva as it works on the integration of Actavis Generics and progresses with its branded pipeline. Teva continues to progress with its branded and generics drugs pipeline and is also looking to strengthen its biosimilar pipeline.



from Biotech News